This summary distills the key insights from BIO-RAD LABORATORIES, INC.'s latest 10-K annual report, offering investors a clear and verified overview of the company's performance, strategy, and outlook.

---

BIO-RAD LABORATORIES, INC. Annual Report - A Deep Dive for Investors

1. Business Overview

Bio-Rad Laboratories stands as a global leader in the life science research and clinical diagnostics markets. The company develops, manufactures, and markets innovative products and solutions essential for academic, government, and corporate research laboratories, as well as for hospitals and reference laboratories. Their tools, equipment, and supplies are crucial for advancing biological research, diagnosing diseases, and developing new treatments.

Bio-Rad operates through two primary segments:

• Life Science: This segment provides research tools, including instruments, software, consumables, and reagents, for areas like protein and gene expression analysis, cell biology, and drug discovery.
• Clinical Diagnostics: This segment develops and manufactures medical diagnostic products. These products help healthcare professionals detect, monitor, and treat conditions such as infectious diseases, diabetes, and autoimmune disorders.

2. Financial Performance

Bio-Rad reported strong financial results for fiscal year 2025, highlighting both resilience and strategic progress.

• Total Revenue: The company achieved $2.95 billion in revenue for 2025, up 5.2% from $2.80 billion in 2024. Increased demand in the Life Science segment, especially for genomic research tools, along with stable Clinical Diagnostics performance, primarily drove this growth.
• Net Income: Bio-Rad reported a net income of $320 million in 2025, an 8.5% increase from $295 million in 2024. This improvement stemmed from effective cost management and higher sales volumes.
• Earnings Per Share (EPS): Diluted EPS stood at $10.75 in 2025, compared to $9.90 in 2024.
• Operating Cash Flow: The company generated robust operating cash flow of $450 million in 2025, demonstrating strong profitability and efficient working capital management. This robust cash flow allows Bio-Rad to internally fund operations and investments.
• Segment Assets: Life Science segment assets grew to $3.49 billion in 2025 from $3.42 billion in 2024. Clinical Diagnostics segment assets increased to $3.92 billion in 2025 from $3.90 billion in 2024.

3. Risk Factors

Investors should consider several key risks that could impact Bio-Rad's operations and financial results:

• Intense Competition: The life science and clinical diagnostics markets are highly competitive, marked by rapid technological advancements. Failure to innovate or keep pace with competitors could erode market share and profitability.
• Regulatory Scrutiny: Bio-Rad operates in a heavily regulated environment. Changes in healthcare regulations, product approvals, or quality standards could increase compliance costs or delay product launches.
• R&D Success: Bio-Rad's growth significantly depends on successful new product research and development. Inefficiently bringing innovative products to market could hinder future revenue growth.
• Supply Chain Vulnerabilities: Reliance on third-party suppliers for raw materials and components, especially from specific regions, exposes the company to risks from geopolitical events, natural disasters, or trade disputes.
• Economic Downturns: Reduced funding for research institutions or decreased healthcare spending during economic recessions could negatively impact demand for Bio-Rad's products.
• Intellectual Property Protection: Protecting their extensive patent portfolio is crucial. Competitor infringement or patent challenges could erode their competitive advantage.

4. Management Discussion & Analysis (MD&A) Highlights

Bio-Rad's 2025 performance featured strategic expansion alongside operational challenges.

In a significant strategic move, Bio-Rad acquired Stilla Technologies in June 2025 for approximately $150 million. Stilla, a pioneer in digital PCR (polymerase chain reaction) technology, offers ultra-sensitive and precise nucleic acid quantification. This acquisition is a game-changer, significantly strengthening Bio-Rad's position in the rapidly expanding field of genomic research and advanced diagnostics, crucial for applications like liquid biopsy, gene therapy development, and infectious disease detection.

Despite strong overall performance, the company faced ongoing supply chain disruptions and inflationary pressures on raw materials and logistics costs. These challenges, particularly affecting certain consumables and components, required proactive management to mitigate their impact on production schedules and profit margins. While crucial for future growth, increased R&D investment also pressured operating expenses in the short term.

Broader market trends also influence Bio-Rad's operations. Growing emphasis on personalized medicine and companion diagnostics drives demand for highly sensitive, precise diagnostic tools. An aging global population increases the incidence of chronic and infectious diseases, boosting demand for clinical diagnostic products. Additionally, continued government and private sector investment in life science research supports the Life Science segment's growth.

5. Financial Health

Bio-Rad maintains robust financial health, supported by strong liquidity and well-managed debt.

• Cash and Investments: At the end of 2025, Bio-Rad held $1.33 billion in cash and cash equivalents, a slight decrease from $1.51 billion in 2024. However, short-term investments increased to $1.07 billion in 2025 from $1.03 billion in 2024. Combined, total liquid assets (cash + short-term investments) reached approximately $2.40 billion in 2025, a slight decrease from $2.54 billion in 2024, primarily due to the Stilla acquisition and capital expenditures. These investments are diversified across corporate debt, U.S. Treasury, foreign government debt, municipal bonds, and asset-backed securities.
• Debt: The company's long-term debt profile remains stable and manageable. Bio-Rad holds two main sets of Senior Notes:
  • One due in 2027, totaling approximately $1.20 billion in both 2025 and 2024.
  • Another due in 2032, also around $1.20 billion in both years.
  • Total Senior Notes amounted to approximately $2.39 billion at the end of both 2025 and 2024.
  • They also carry smaller, stable amounts of other long-term debt and finance lease obligations (approximately $11-12 million annually).
• Liquidity: With substantial cash reserves, diversified investments, and an undrawn $500 million revolving credit facility, Bio-Rad possesses ample liquidity to fund operations, strategic initiatives, and manage debt. A healthy debt-to-equity ratio indicates a balanced capital structure.

6. Future Outlook

Bio-Rad maintains a cautiously optimistic outlook for the coming year and beyond, driven by strategic investments and favorable market trends. The integration of Stilla Technologies will meaningfully contribute to Life Science segment revenue growth, especially as digital PCR applications expand. Bio-Rad anticipates continued demand in both core segments, fueled by an aging global population, increasing chronic disease prevalence, and sustained biomedical research investment.

Management projects revenue growth in the range of 4-6% for fiscal year 2026, focusing on expanding margins through product mix optimization and cost discipline. Bio-Rad's strategy emphasizes organic innovation and targeted acquisitions to maintain technological leadership and capture emerging market opportunities. The company plans to continue investing approximately 12-14% of revenue into R&D to fuel future innovation and expand its global footprint, especially in emerging markets.

Bio-Rad is well-positioned to capitalize on macro trends like the increasing adoption of personalized medicine, the aging global population, and sustained R&D funding. They also aim to leverage healthcare's digital transformation by integrating instruments with advanced software and data analytics platforms. While navigating an evolving regulatory landscape, particularly stricter requirements for diagnostic products (e.g., IVDR in Europe), Bio-Rad's strong R&D capabilities and strategic approach will likely support continued growth.

7. Competitive Position

Bio-Rad holds a strong competitive position, leveraging its broad product portfolio, established global distribution network, and commitment to innovation. In the Life Science segment, Bio-Rad competes with giants like Thermo Fisher Scientific and Danaher, differentiating through specialized technologies and application expertise. In Clinical Diagnostics, the company holds leading positions in areas like diabetes monitoring and infectious disease testing, competing with companies such as Abbott and Roche.

The acquisition of Stilla Technologies significantly enhances Bio-Rad's competitive edge in the high-growth digital PCR market, allowing them to offer cutting-edge solutions difficult for many competitors to quickly replicate. Their strong, decades-long brand reputation for quality and reliability also significantly contributes to their enduring market presence and customer loyalty.